KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Enterprise Value: 2010-2024

Historic Enterprise Value for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $1.5 billion.

  • Supernus Pharmaceuticals' Enterprise Value rose 82.40% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $958.8 million, marking a year-over-year increase of 130.93%. This contributed to the annual value of $1.5 billion for FY2024, which is 16.36% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Enterprise Value stood at $1.5 billion for FY2024, which was up 16.36% from $1.3 billion recorded in FY2023.
  • Supernus Pharmaceuticals' Enterprise Value's 5-year high stood at $1.5 billion during FY2024, with a 5-year trough of $903.0 million in FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Enterprise Value averaged around $1.4 billion, with its median value being $1.5 billion (2022).
  • Its Enterprise Value has fluctuated over the past 5 years, first soared by 34.11% in 2021, then fell by 9.59% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Enterprise Value (Yearly) stood at $903.0 million in 2020, then skyrocketed by 34.11% to $1.2 billion in 2021, then climbed by 21.13% to $1.5 billion in 2022, then fell by 9.59% to $1.3 billion in 2023, then increased by 16.36% to $1.5 billion in 2024.